Ireland to reimburse Friedreich's ataxia drug Skyclarys from 1 October

The HSE approved funding for Skyclarys last month, and Fianna Fáil now confirms reimbursement will be in place from 1 October. This is a routine policy implementation, not a market-moving event. The drug treats a rare neuromuscular disease, and the announcement confirms the timeline for patient access.